EP3236985A1 - Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers - Google Patents

Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Info

Publication number
EP3236985A1
EP3236985A1 EP15813809.9A EP15813809A EP3236985A1 EP 3236985 A1 EP3236985 A1 EP 3236985A1 EP 15813809 A EP15813809 A EP 15813809A EP 3236985 A1 EP3236985 A1 EP 3236985A1
Authority
EP
European Patent Office
Prior art keywords
peptide
cancer
cells
cell
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15813809.9A
Other languages
German (de)
English (en)
Other versions
EP3236985B2 (fr
EP3236985B1 (fr
Inventor
Toni Weinschenk
Andrea Mahr
Jens Fritsche
Phillip Müller
Anita WIEBE
Sarah KUTSCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3236985(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL19199098T priority Critical patent/PL3616706T3/pl
Priority to DK19170191.1T priority patent/DK3545965T3/da
Priority to EP19199098.5A priority patent/EP3616706B1/fr
Priority to SI201531025T priority patent/SI3236985T2/sl
Priority to DK19199098.5T priority patent/DK3616706T3/da
Priority to HRP20192212TT priority patent/HRP20192212T4/hr
Priority to EP19170191.1A priority patent/EP3545965B1/fr
Priority to RS20191606A priority patent/RS59836B2/sr
Priority to DK19199101.7T priority patent/DK3626729T3/da
Priority to MA41237A priority patent/MA41237B1/fr
Priority to PL19199101T priority patent/PL3626729T3/pl
Priority to EP19199125.6A priority patent/EP3626731B1/fr
Priority to EP19199106.6A priority patent/EP3626730A1/fr
Priority to PL19199125T priority patent/PL3626731T3/pl
Priority to PL19170191T priority patent/PL3545965T3/pl
Priority to DK19199125.6T priority patent/DK3626731T3/da
Priority to EP24199595.0A priority patent/EP4461371A3/fr
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to EP19199114.0A priority patent/EP3620168A1/fr
Priority to EP20172206.3A priority patent/EP3715357B1/fr
Priority to EP19199101.7A priority patent/EP3626729B1/fr
Priority to PL15813809.9T priority patent/PL3236985T5/pl
Publication of EP3236985A1 publication Critical patent/EP3236985A1/fr
Publication of EP3236985B1 publication Critical patent/EP3236985B1/fr
Application granted granted Critical
Priority to CY20211100869T priority patent/CY1124533T1/el
Priority to CY20211101070T priority patent/CY1124846T1/el
Priority to CY20211101071T priority patent/CY1124847T1/el
Priority to CY20211101104T priority patent/CY1124813T1/el
Publication of EP3236985B2 publication Critical patent/EP3236985B2/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Definitions

  • Novel peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers are novel peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers
  • the present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods.
  • the present invention relates to the immunotherapy of cancer.
  • the present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients.
  • Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
  • MHC major histocompatibility complex
  • the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
  • Hepatocellular carcinoma is one of the most common tumors in the world and accounts for about 6% of all new cancer cases diagnosed worldwide. In 2012 about 782,000 new cases of HCC occurred in the world, making it the fifth most common cancer in men (554,000 cases) and the ninth in women (228,000 cases) (http://globocan.iarc.fr). HCC is the most common primary liver malignancy accounting for over 80% of all adult primary liver cancers.
  • HCC The distribution of HCC varies geographically, and rates of incidence depend on gender.
  • the age-standardized incidence rate (ASR) of HCC in men is highest in Eastern Asia (31.9) and South-Eastern Asia (22.2), intermediate in Southern Europe (9.5) and Northern America (9.3) and lowest in Northern Europe (4.6) and South-Central Asia (3.7).
  • Incident rates of HCC in women are lower than male ASRs.
  • the highest ASR in women occurs in Eastern Asia (10.2) and Western Africa (8.1 ), the lowest in Northern Europe (1.9) and Micronesia (1 .6).
  • the overall prognosis for patients with HCC is poor.
  • the 5-year relative survival rate (5Y-RSR) from HCC is about 15%, depending on the stage at the time of diagnosis.
  • 5Y-RSR is about 28%.
  • 5Y-RSRs are 7% and 2%, respectively.
  • Cirrhosis is the most important one. Cirrhosis often occurs alongside alcohol abuse or HBV or HCV infections, but can also be caused by metabolic diseases like type II diabetes. As a result, healthy liver tissue gets replaced by scar tissue, which increases the risk of cancer development.
  • liver transplant Disease management depends on the tumor stage at the time of diagnosis and the overall condition of the liver. If possible, parts of the liver (partial hepatectomy) or the whole organ (liver resection) is removed by surgery. Especially patients with small or completely resectable tumors are qualified to receive a liver transplant.
  • a probe is injected into the liver and the tumor is destroyed by radio or microwaves or cryotherapy.
  • embolization procedures the blood supply of the tumor is blocked by mechanical or chemical means. High energy radio waves can be used to destroy the tumor in radiation therapy.
  • Chemotherapy against HCC includes combinations of doxorubicin, 5-fluorouracil and cisplatin for systemic therapy and doxorubicin, floxuridine and mitomycin C for hepatic artery infusions.
  • most HCC show a high resistance to chemotherapeutics (Enguita-German and Fortes, 2014).
  • Therapeutic options in advanced non-resectable HCC are limited to Sorafenib, a multi- tyrosine kinase inhibitor (Chang et al., 2007; Wilhelm et al., 2004). Sorafenib is the only systemic drug confirmed to increase survival by about 3 months and currently represents the only experimental treatment option for such patients (Chapiro et al., 2014; Llovet et al., 2008).
  • Cytokines have been used to activate subsets of immune cells and/or increase the tumor immunogenicity (Reinisch et al., 2002; Sangro et al., 2004).
  • Other trials have focused on the infusion of Tumor-infiltrating lymphocytes or activated peripheral blood lymphocytes (Shi et al., 2004a; Takayama et al., 1991 ; Takayama et al., 2000).
  • the present invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 300 or a variant sequence thereof which is at least 80%, preferably at least 90%, homologous (preferably at least 80% or at least 90% identical) to SEQ ID NO: 1 to SEQ ID NO: 300, wherein said variant binds to MHC and/or induces T cells cross-reacting with said peptide, or a pharmaceutical acceptable salt thereof, wherein said peptide is not the underlying full-length polypeptide.
  • the present invention further relates to a peptide of the present invention comprising a sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 300 or a variant thereof, which is at least 80%, preferably at least 88%, homologous (preferably at least 80% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 300, wherein said peptide or variant thereof has an overall length of between 8 and 100, preferably between 8 and 30, and most preferred of between 8 and 14 amino acids.
  • the following tables show the peptides according to the present invention, their respective SEQ ID NOs, and the prospective source (underlying) genes for these peptides. All peptides in Table 1 bind to HLA-A * 02, peptides in Table 2 bind to HLA- A * 24 alleles. The peptides in Table 3 have been disclosed before in large listings as results of high-throughput screenings with high error rates or calculated using algorithms, but have not been associated with cancer at all before. They bind to HLA- A * 02. The peptides in Table 4 are additional peptides that may be useful in combination with the other peptides of the invention. Peptides bind A * 02 or, where indicated, A * 24. The peptides in Table 5 are furthermore useful in the diagnosis and/or treatment of various malignancies that involve an over-expression or over-presentation of the respective underlying polypeptide.
  • IYADVGEEF 100302182, 1 1052 MIR1279, CPSF6
  • VLADFGARV 1 14899,23600 C1 QTNF3,AMACR
  • the present invention furthermore generally relates to the peptides according to the present invention for use in the treatment of proliferative diseases, such as, for example, pancreatic cancer, colon or rectal cancer, kidney cancer, brain cancer, and/or leukemias.
  • proliferative diseases such as, for example, pancreatic cancer, colon or rectal cancer, kidney cancer, brain cancer, and/or leukemias.
  • the peptides - alone or in combination - according to the present invention selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 300. More preferred are the peptides - alone or in combination - selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 124 (see Table 1 ), preferably for A * 02 binding, and from the group consisting of SEQ ID NO: 187 to SEQ ID NO: 218 (see Table 2) preferably for A * 24 binding, and their uses in the immunotherapy of HCC, brain cancer, kidney cancer, pancreatic cancer, colon or rectal cancer or leukemia, and preferably HCC.
  • the peptides according to the present invention can also be used in the immunotherapy of other indications.
  • the tables show, for selected peptides on which additional tumor types they were found showing over-presentation (including specific presentation) on more than 5% of the measured tumor samples, or presentation on more than 5% of the measured tumor samples with a ratio of geometric means tumor vs normal tissues being larger than 3.
  • Over-presentation is defined as higher presentation on the tumor sample as compared to the normal sample with highest presentation.
  • adipose tissue adrenal gland, blood cells, blood vessel, bone marrow, brain, cartilage, esophagus, eye, gallbladder, heart, kidney, large intestine, liver, lung, lymph node, nerve, pancreas, parathyroid gland, peritoneum, pituitary, pleura, salivary gland, skeletal muscle, skin, small intestine, spleen, stomach, thyroid gland, trachea, ureter, urinary bladder.
  • NSCLC NSCLC, SCLC, GC, Melanoma, OC, Esophageal
  • NSCLC NSCLC, CRC, MCC, OC, Urinary bladder cancer
  • NSCLC NSCLC
  • SCLC BRCA
  • MCC Melanoma
  • OC Esophageal Cancer
  • Urinary bladder cancer Uterine
  • NSCLC NSCLC, GC, BRCA, Melanoma, Esophageal Cancer
  • NSCLC NSCLC
  • SCLC BRCA
  • MCC Melanoma
  • OC OC
  • NSCLC NSCLC, PrC, MCC, Melanoma, OC, Esophageal
  • NSCLC NSCLC
  • SCLC PrC
  • BRCA Melanoma
  • OC OC
  • NSCLC NSCLC
  • SCLC SCLC
  • OC Urinary bladder cancer
  • Uterine Uterine
  • NSCLC NSCLC, CLL, Melanoma, OC, Esophageal Cancer
  • NSCLC NSCLC
  • SCLC SCLC
  • GC OC
  • Urinary bladder cancer
  • NSCLC NSCLC, SCLC, PrC, Melanoma, OC, Urinary bladder
  • NSCLC NSCLC
  • SCLC PrC
  • CLL CLL
  • BRCA Melanoma
  • OC OC
  • NSCLC NSCLC, SCLC, GC, Melanoma, OC, Esophageal
  • NSCLC NSCLC, SCLC, RCC, PrC, BRCA, Melanoma
  • NSCLC NSCLC
  • SCLC RCC
  • Brain Cancer CLL
  • BRCA OC
  • NSCLC NSCLC, SCLC, PrC, Melanoma, OC, Urinary bladder
  • NSCLC NSCLC, SCLC, PrC, BRCA, MCC, OC, Gallbladder
  • NSCLC NSCLC, SCLC, Brain Cancer, BRCA, Melanoma,
  • NSCLC NSCLC, SCLC, PrC, Melanoma, Urinary bladder
  • NSCLC NSCLC
  • SCLC CLL
  • BRCA MCC
  • Melanoma Melanoma
  • OC Esophageal Cancer
  • Urinary bladder cancer Uterine
  • NSCLC NSCLC
  • SCLC CRC, PrC, BRCA, Melanoma, OC
  • NSCLC NSCLC, RCC, GC, BRCA, Melanoma, Esophageal
  • SCLC SCLC
  • MCC Melanoma
  • OC Urinary bladder cancer
  • NSCLC NSCLC, SCLC, PrC, MCC, Melanoma, Urinary
  • NSCLC NSCLC, SCLC, BRCA, MCC, Melanoma, Esophageal
  • NSCLC NSCLC
  • SCLC Brain Cancer
  • NSCLC NSCLC
  • SCLC CLL
  • BRCA Melanoma
  • OC OC
  • NSCLC Melanoma
  • Urinary bladder cancer Urinary bladder cancer
  • NSCLC NSCLC, CLL, BRCA, Melanoma, OC, Esophageal
  • NSCLC NSCLC
  • SCLC CLL
  • OC Urinary bladder cancer
  • NSCLC NSCLC
  • SCLC PrC
  • BRCA MCC
  • Melanoma OC
  • NSCLC non-small cell lung cancer
  • SCLC small cell lung cancer
  • RCC kidney cancer
  • CRC colon or rectum cancer
  • GC stomach cancer
  • HCC liver cancer
  • PC pancreatic cancer
  • PrC prostate cancer
  • MCC Merkel cell carcinoma
  • OC ovarian cancer
  • NHL non-Hodgkin lymphoma
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia.
  • another aspect of the present invention relates to the use of at least one peptide according to the present invention according to any one of SEQ ID No. 1 , 14, 15, 41 , 43, 58, 59, 60, 81 , 121 , 135, 139, 144, 176, 236, 248, 275, 276, 283, 286, 288, 289, 290, 291 , 300, 302, 304, 308, 313, 316, 317, 325, 326, 329, 331 , 334, 342, and 343 for the - in one preferred embodiment combined - treatment of pancreatic cancer.
  • another aspect of the present invention relates to the use of at least one peptide according to the present invention according to SEQ ID No. 6, 15, 16, 22, 26, 30, 34, 36, 47, 59, 65, 69, 70, 77, 80, 81 , 88, 121 , 123, 125, 127, 133, 137, 139, 169, 172, 176, 181 , 186, 221 , 223, 229, 230, 231 , 232, 233, 234, 236, 237, 238, 244, 247, 249, 250, 251 , 255, 260, 261 , 266, 269, 271 , 274, 275, 282, 285, 289, 290, 291 , 293, 297, 301 , 302, 304, 306, 310, 313, 316, 317, 319, 327, 328, 329, 330, 331 , 332, 334, and 342 for the - in one preferred embodiment combined - treatment of colon
  • another aspect of the present invention relates to the use of at least one peptide according to the present invention according to SEQ ID No. 10, 14, 15, 22, 36, 39, 54, 55, 60, 72, 77, 81 , 90, 96, 1 12, 1 16, 1 19, 121 , 133, 137, 138, 148, 169, 170, 172, 177, 186, 187, 189, 192, 197, 198, 203, 206, 219, 221 , 229, 230, 233, 234, 236, 255, 260, 270, 272, 275, 277, 278, 279, 281 , 282, 285, 289, 291 , 292, 295, 296, 297, 301 , 302, 305, 308, 31 1 , 313, 315, 316, 319, 321 , 324, 328, 329, 333, 334, 335, 336, and 346 for the - in one preferred embodiment combined - treatment of kidney cancer.
  • another aspect of the present invention relates to the use of at least one peptide according to the present invention according to SEQ ID No. 14, 15, 16, 17, 36, 39, 47, 51 , 54, 65, 88, 101 , 123, 125, 133, 134, 135, 137, 141 , 147, 161 , 166, 169, 176, 179, 184, 186, 187, 189, 191 , 192, 193, 194, 195, 196, 197, 199, 203, 206, 208, 214, 220, 221 , 224, 229, 230, 231 , 234, 238, 239, 244, 245, 250, 251 , 255, 258, 259, 260, 268, 269, 270, 271 , 272, 278, 279, 282, 295, 297, 302, 304, 305, 306, 309, 310, 31 1 , 312, 313, 316, 317, 319, 321 , 3
  • Another aspect of the present invention relates to the use of at least one peptide according to the present invention according to SEQ ID No. 172, 173, 240, 250, 287, 299, 302, 334, and 335 for the - in one preferred embodiment combined - treatment of CLL.
  • the peptides as listed in Table 5B as above can form the basis for the - in one preferred embodiment combined - treatment of the diseases as indicated.
  • another aspect of the present invention relates to the use of the peptides according to the present invention for the - preferably combined - treatment of a proliferative disease selected from the group of HCC, brain cancer, kidney cancer, pancreatic cancer, colon or rectal cancer, and leukemia.
  • a proliferative disease selected from the group of HCC, brain cancer, kidney cancer, pancreatic cancer, colon or rectal cancer, and leukemia.
  • the present invention furthermore relates to peptides according to the present invention that have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-l or - in an elongated form, such as a length-variant - MHC class -II.
  • MHC human major histocompatibility complex
  • the present invention further relates to the peptides according to the present invention wherein said peptides (each) consist or consist essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 300.
  • the present invention further relates to the peptides according to the present invention, wherein said peptide is modified and/or includes non-peptide bonds.
  • the present invention further relates to the peptides according to the present invention, wherein said peptide is part of a fusion protein, in particular fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (li), or fused to (or into the sequence of) an antibody, such as, for example, an antibody that is specific for dendritic cells.
  • a fusion protein in particular fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (li), or fused to (or into the sequence of) an antibody, such as, for example, an antibody that is specific for dendritic cells.
  • the present invention further relates to a nucleic acid, encoding the peptides according to the present invention.
  • the present invention further relates to the nucleic acid according to the present invention that is DNA, cDNA, PNA, RNA or combinations thereof.
  • the present invention further relates to an expression vector capable of expressing and/or expressing a nucleic acid according to the present invention.
  • the present invention further relates to a peptide according to the present invention, a nucleic acid according to the present invention or an expression vector according to the present invention for use in the treatment of diseases and in medicine, in particular in the treatment of diseases including cancer and autoimmune / inflammatory / immune pathological diseases.
  • the present invention further relates to antibodies against the peptides according to the present invention or complexes of said peptides according to the present invention with MHC, and methods of making these.
  • the present invention further relates to T-cell receptors (TCRs), in particular soluble TCR (sTCRs) and cloned TCRs engineered into autologous or allogeneic T cells, and methods of making these, as well as NK cells or other cells bearing said TCR or cross- reacting with said TCRs.
  • TCRs T-cell receptors
  • sTCRs soluble TCR
  • cloned TCRs engineered into autologous or allogeneic T cells
  • the antibodies and TCRs are additional embodiments of the immunotherapeutic use of the peptides according to the invention at hand.
  • the present invention further relates to a host cell comprising a nucleic acid according to the present invention or an expression vector as described before.
  • the present invention further relates to the host cell according to the present invention that is an antigen presenting cell, and preferably is a dendritic cell.
  • the present invention further relates to a method for producing a peptide according to the present invention, said method comprising culturing the host cell according to the present invention, and isolating the peptide from said host cell or its culture medium.
  • the present invention further relates to said method according to the present invention, wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or artificial antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.
  • the present invention further relates to the method according to the present invention, wherein the antigen-presenting cell comprises an expression vector capable of expressing or expressing said peptide containing SEQ ID No. 1 to SEQ ID No.: 300, preferably containing SEQ ID No. 1 to SEQ ID No. 124, and SEQ ID No. 187 to SEQ ID No.: 218 or a variant amino acid sequence.
  • the present invention further relates to activated T cells, produced by the method according to the present invention, wherein said T cell selectively recognizes a cell which expresses a polypeptide comprising an amino acid sequence according to the present invention.
  • the present invention further relates to a method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising any amino acid sequence according to the present invention, the method comprising administering to the patient an effective number of T cells as produced according to the present invention.
  • the present invention further relates to the use of any peptide as described, the nucleic acid according to the present invention, the expression vector according to the present invention, the cell according to the present invention, the activated T lymphocyte, the T cell receptor or the antibody or other peptide- and/or peptide-MHC-binding molecules according to the present invention as a medicament or in the manufacture of a medicament.
  • the medicament is active against cancer.
  • said medicament is for a cellular therapy, a vaccine or a protein based on a soluble TCR or antibody.
  • the present invention further relates to a use according to the present invention, wherein said cancer cells are HCC, brain cancer, kidney cancer, pancreatic cancer, colon or rectal cancer or leukemia, and preferably HCC cells.
  • the present invention further relates to particular marker proteins and biomarkers based on the peptides according to the present invention, herein called "targets" that can be used in the diagnosis and/or prognosis of HCC.
  • targets are particular marker proteins and biomarkers based on the peptides according to the present invention, herein called "targets” that can be used in the diagnosis and/or prognosis of HCC.
  • the present invention also relates to the use of these novel targets in the context of cancer treatment.
  • MHC-molecules There are two classes of MHC-molecules, MHC class I and MHC class II.
  • MHC molecules are composed of an alpha heavy chain and beta-2-microglobulin (MHC class I receptors) or an alpha and a beta chain (MHC class II receptors), respectively. Their three-dimensional conformation results in a binding groove, which is used for non- covalent interaction with peptides.
  • MHC class I molecules can be found on most nucleated cells. They present peptides that result from proteolytic cleavage of predominantly endogenous proteins, defective ribosomal products (DRIPs) and larger peptides.
  • DRIPs defective ribosomal products
  • MHC class II molecules can be found predominantly on professional antigen presenting cells (APCs), and primarily present peptides of exogenous or transmembrane proteins that are taken up by APCs during endocytosis, and are subsequently processed.
  • APCs professional antigen presenting cells
  • Complexes of peptide and MHC class I are recognized by CD8-positive T cells bearing the appropriate TCR (T-cell receptor), whereas complexes of peptide and MHC class II molecules are recognized by CD4-positive-helper-T cells bearing the appropriate TCR. It is well known that the TCR, the peptide and the MHC are thereby present in a stoichiometric amount of 1 :1 :1.
  • CD4-positive helper T cells play an important role in inducing and sustaining effective responses by CD8-positive cytotoxic T cells.
  • TAA tumor associated antigens
  • the identification of CD4-positive T-cell epitopes derived from tumor associated antigens (TAA) is of great importance for the development of pharmaceutical products for triggering anti-tumor immune responses (Gnjatic S, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8862-7).
  • T helper cells support a cytotoxic T cell- (CTL-) friendly cytokine milieu Mortara L, et al.
  • CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
  • MHC class II molecules In the absence of inflammation, expression of MHC class II molecules is mainly restricted to cells of the immune system, especially professional antigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells.
  • APC professional antigen-presenting cells
  • monocytes e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells.
  • monocytes e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells.
  • MHC class II molecules In cancer patients, cells of the tumor have been found to express MHC class II molecules (Dengjel J, et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1 ):4163-70).
  • Elongated (longer) peptides of the invention can act as MHC class II active epitopes.
  • T- helper cells activated by MHC class II epitopes, play an important role in orchestrating the effector function of CTLs in anti-tumor immunity.
  • T-helper cell epitopes that trigger a T-helper cell response of the TH1 type support effector functions of CD8-positive killer T cells, which include cytotoxic functions directed against tumor cells displaying tumor- associated peptide/MHC complexes on their cell surfaces. In this way tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.
  • CD4-positive T cells are sufficient for inhibiting manifestation of tumors via inhibition of angiogenesis by secretion of interferon-gamma (IFNy).
  • IFNy interferon-gamma
  • CD4 T cells direct anti-tumor effectors (Braumuller et al., 2013; Tran et al., 2014).
  • HLA class II molecules Since the constitutive expression of HLA class II molecules is usually limited to immune cells, the possibility of isolating class II peptides directly from primary tumors was not considered possible. However, Dengjel et al. were successful in identifying a number of MHC Class II epitopes directly from tumors (WO 2007/028574, EP 1 760 088 B1 ).
  • the antigens that are recognized by the tumor specific cytotoxic T lymphocytes can be molecules derived from all protein classes, such as enzymes, receptors, transcription factors, etc. which are expressed and, as compared to unaltered cells of the same origin, usually up-regulated in cells of the respective tumor.
  • MHC-class-l- binding peptides are usually 8-12 amino acid residues in length and usually contain two conserved residues ("anchors") in their sequence that interact with the corresponding binding groove of the MHC-molecule. In this way each MHC allele has a "binding motif" determining which peptides can bind specifically to the binding groove.
  • peptides In the MHC class I dependent immune reaction, peptides not only have to be able to bind to certain MHC class I molecules expressed by tumor cells, they subsequently also have to be recognized by T cells bearing specific T cell receptors (TCR).
  • TCR T cell receptors
  • the current classification of tumor associated antigens comprises the following major groups:
  • Cancer-testis antigens The first TAAs ever identified that can be recognized by T cells belong to this class, which was originally called cancer-testis (CT) antigens because of the expression of its members in histologically different human tumors and, among normal tissues, only in spermatocytes/spermatogonia of testis and, occasionally, in placenta. Since the cells of testis do not express class I and II HLA molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be considered as immunologically tumor-specific.
  • CT antigens are the MAGE family members or NY-ESO-1 .
  • TAAs Differentiation antigens: These TAAs are shared between tumors and the normal tissue from which the tumor arose; most are found in melanomas and normal melanocytes. Many of these melanocyte lineage-related proteins are involved in the biosynthesis of melanin and are therefore not tumor specific but nevertheless are widely used for cancer immunotherapy. Examples include, but are not limited to, tyrosinase and Melan-A/MART-1 for melanoma or PSA for prostate cancer.
  • TAAs Overexpressed TAAs: Genes encoding widely expressed TAAs have been detected in histologically different types of tumors as well as in many normal tissues, generally with lower expression levels. It is possible that many of the epitopes processed and potentially presented by normal tissues are below the threshold level for T-cell recognition, while their overexpression in tumor cells can trigger an anticancer response by breaking previously established tolerance. Prominent examples for this class of TAAs are Her-2/neu, Survivin, Telomerase or WT1.
  • Tumor specific antigens arise from mutations of normal genes (such as ⁇ -catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and/or progression. Tumor specific antigens are generally able to induce strong immune responses without bearing the risk for autoimmune reactions against normal tissues. On the other hand, these TAAs are in most cases only relevant to the exact tumor on which they were identified and are usually not shared between many individual tumors. Tumor-specificity (or -association) of a peptide may also arise if the peptide originates from a tumor- (-associated) exon in case of proteins with tumor-specific (-associated) isoforms.
  • TAAs arising from abnormal post-translational modifications may arise from proteins which are neither specific nor overexpressed in tumors but nevertheless become tumor associated by posttranslational processes primarily active in tumors. Examples for this class arise from altered glycosylation patterns leading to novel epitopes in tumors as for MUC1 or events like protein splicing during degradation which may or may not be tumor specific.
  • Oncoviral proteins are viral proteins that may play a critical role in the oncogenic process and, because they are foreign (not of human origin), they can evoke a T-cell response. Examples of such proteins are the human papilloma type 16 virus proteins, E6 and E7, which are expressed in cervical carcinoma.
  • the antigen should be expressed mainly by tumor cells and not, or in comparably small amounts, by normal healthy tissues.
  • the peptide should be over-presented by tumor cells as compared to normal healthy tissues. It is furthermore desirable that the respective antigen is not only present in a type of tumor, but also in high concentrations (i.e. copy numbers of the respective peptide per cell).
  • Tumor-specific and tumor-associated antigens are often derived from proteins directly involved in transformation of a normal cell to a tumor cell due to their function, e.g.
  • tumor-associated antigens may also be targets of a vaccination approach (Singh-Jasuja et al., 2004). It is essential that epitopes are present in the amino acid sequence of the antigen, in order to ensure that such a peptide ("immunogenic peptide"), being derived from a tumor associated antigen, leads to an in vitro or in vivo T-cell-response.
  • any peptide able to bind an MHC molecule may function as a T-cell epitope.
  • a prerequisite for the induction of an in vitro or in vivo T-cell-response is the presence of a T cell having a corresponding TCR and the absence of immunological tolerance for this particular epitope.
  • TAAs are a starting point for the development of a T cell based therapy including but not limited to tumor vaccines.
  • the methods for identifying and characterizing the TAAs are based on the use of T-cells that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumors and normal tissues.
  • the identification of genes over-expressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens being transcribed from these genes in an immune therapy. This is because only an individual subpopulation of epitopes of these antigens are suitable for such an application since a T cell with a corresponding TCR has to be present and the immunological tolerance for this particular epitope needs to be absent or minimal. In a very preferred embodiment of the invention it is therefore important to select only those over- or selectively presented peptides against which a functional and/or a proliferating T cell can be found.
  • a functional T cell is defined as a T cell, which upon stimulation with a specific antigen can be clonally expanded and is able to execute effector functions ("effector T cell").
  • the immunogenicity of the underlying peptides is secondary.
  • the presentation is the determining factor.
  • COL18A1 Differential expression of COL18A1 was reported for bladder cancer, rhabdoid tumors and ovarian carcinoma and specific polymorphisms within the gene were shown to increase the risk for sporadic breast cancer (Fang et al., 2013; Gadd et al., 2010; Peters et al., 2005; Lourenco et al., 2006).
  • CPB2 chronic promyelocytic leukemia
  • CRP an acute phase protein synthesized in the liver
  • CRYZ is a target gene of the tumor-suppressor p53 (Bansal et al., 201 1 ). Its encoded protein zeta-crystallin was shown to directly interact with the mRNA of the anti-apoptotic molecule bcl-2 and to stabilize the over-expression of bcl-2 in T-cell acute lymphocytic leukemia (Lapucci et al., 2010). Over-expression of CSRP2 is associated with de-differentiation of hepatocellular carcinoma (Midorikawa et al., 2002).
  • CYB5A encodes an enzyme which detoxifies carcinogenic molecules and is a prognostic factor for pancreatic cancer (Blanke et al., 2014; Giovannetti et al., 2014).
  • CYP27A1 Increased expression levels of CYP27A1 are associated with endometrial carcinoma, breast cancer and colorectal cancer (Bergada et al., 2014; Nelson et al., 2013; Matusiak and Benya, 2007).
  • CYP2E1 Over-expression of CYP2E1 was reported in colorectal cancer, specific polymorphisms are associated with bladder and lung cancer and in breast cancer cells (Ye et al., 2014; Patel et al., 2014; Deng et al., 2014; Leung et al., 2013).
  • CYP2J2 is an enzyme, which was shown to be over-expressed in a variety of human cancers, including esophageal, lung, breast, stomach, liver and colon cancer (Jiang et al., 2005; Narjoz et al., 2014).
  • CYP4F8 was shown to be highly expressed in prostate cancer (Vainio et al., 201 1 ). CYP4F2 and CYP4F3 were both shown to be over-expressed in pancreatic ductal adenocarcinoma and CYP4F2 alone in ovarian cancer (Gandhi et al., 2013; Alexanian et al., 2012).
  • CYP4F1 1 was shown to be regulated by NF- ⁇ and p53 (Kalsotra et al., 2004; Bell and Strobel, 2012; Goldstein et al., 2013).
  • CYPAF12 Genetic variants of CYPAF12 are significantly associated with gemcitabine response in pancreatic cancer patients (Goldstein et al., 2013; Harris et al., 2014). High levels of DAP3 correlate on the one hand with better responses to chemotherapy in gastric cancer and better clinical outcome in breast cancer, but on the other hand over-expression of DAP3 was reported in thyroid oncocytic tumors and invasive glioblastoma (Jia et al., 2014; Wazir et al., 2012; Jacques et al., 2009; Mariani et al., 2001 ).
  • PEX19 is essential for peroxisomal biogenesis, but was also shown to directly interact with p19ARF, ultimately leading to a retention of this factor in the cytoplasm and to an inactivation of p53 tumor-suppressive function (Sugihara et al., 2001 ).
  • DDX1 1 belonging to the DEAH family of DNA helicases, is highly expressed in advanced melanoma (Bhattacharya et al., 2012).
  • NME4 is a nucleoside diphosphate kinase, over-expressed in colon and gastric cancer, as well as in myelodysplastic syndrome, in the latter disease being associated with poor prognosis (Kracmarova et al., 2008; Seifert et al., 2005).
  • DENND5B acts as GDP-GTP exchange factor to activate Rab-GTPases (Yoshimura et al., 2010).
  • DIEXF was shown to mediate the non-proteasomal degradation of the tumor- suppressor p53 (Tao et al., 2013).
  • DOCK7 is a guanine nucleotide exchange factor, which was shown to be over- expressed in glioblastoma and to increase glioblastoma cell invasion in response to HGF by activating Rac-1 (Murray et al., 2014).
  • DRG2 In hepatocellular carcinoma cell lines, DRG2 was shown to be down-regulated during chemotherapeutic drug induced apoptosis, and over-expression of DRG2 inhibits doxorubicin induced apoptosis in these cells (Chen et al., 2012a).
  • DROSHA one of the two critical enzymes in microRNA biosynthesis, is over-expressed in a number of cancers including gastrointestinal tumors, breast cancer and cervical cancer and appears to enhance proliferation, colony formation and migration of tumor cells (Avery-Kiejda et al., 2014; Havens et al., 2014; Zhou et al., 2013b).
  • SNPs in the DUSP14 gene are associated with altered melanoma risk (Yang et al., 2014a; Liu et al. , 2013b).
  • EEF2 protein was shown to be over-expressed in lung, esophageal, pancreatic, breast and prostate cancer, in glioblastoma multiforme and in non-Hodgkin's lymphoma and to play an oncogenic role in cancer cell growth (Oji et al., 2014; Zhu et al., 2014a).
  • EIF2B5 encodes one subunit of the translation initiation factor B. Single nucleotide polymorphisms in this gene were described to be associated with survival time in ovarian cancer (Goode et al., 2010).
  • EIF3A the eukaryotic translation initiation factor 3, subunit A is over-expressed in cancers of breast, lung, cervix, esophagus, stomach and colon and was shown to be involved in cell cycle regulation (Dong and Zhang, 2006).
  • EIF4E is a potent oncogene elevated in up to 30% of human malignancies, including carcinomas of the breast, prostate, lung, head, and neck as well as in many leukemias and lymphomas (Carroll and Borden, 2013).
  • ELOVL2 was shown to be over-expressed in hepatocellular carcinoma (Jakobsson et al., 2006; Zekri et al., 2012).
  • EPRS encodes a multifunctional aminoacyl-tRNA synthetase, which was reported to be a tumor-associated antigen in colon cancer (Line et al., 2002).
  • EXOSC4 promotor activity is increased in hepatocellular carcinoma, due to DNA hypomethylation. EXOSC4 effectively and specifically inhibits cancer cell growth and cell invasive capacities (Drazkowska et al., 2013; Stefanska et al., 2014).
  • the hydrolytic enzyme FUCA2 was found to be essential for H. pylori adhesion to human gastric cancer cells (Liu et al., 2009a).
  • GABRQ encodes the GABAA receptor theta subunit. GABA was shown to stimulate human hepatocellular carcinoma growth through the over-expressed GABAA receptor theta subunit (Li et al., 2012).
  • GGH GGF
  • GLUL is over-expressed in human breast carcinoma cells and astrocytomas (Zhuang et al., 201 1 ; Collins et al., 1997; Christa et al., 1994; Cadoret et al., 2002).
  • GNPAT was reported to be implicated in growth inhibition and apoptosis induction in metastatic melanoma (Ofman et al., 2001 ; Qin et al., 2013). Deletions in the chromosomal region of GOLGA4 have been reported in cervical carcinoma and in-frame mRNA fusion of GOLGA4 with PDGFRB in myeloproliferative neoplasms (Senchenko et al., 2003; Hidalgo-Curtis et al., 2010).
  • GPAM is expressed in human breast cancer, which is associated with changes in the cellular metabolism and better overall survival (Brockmoller et al., 2012).
  • GPT hepatitis C virus-induced hepatocellular carcinoma
  • GRB14 has been shown to be up-regulated in breast cancer, where high expression was significantly associated with better disease-free and overall survival (Huang et al., 2013; Balogh et al., 2012).
  • HSPA8 was shown to be over-expressed in esophageal squamous cell carcinoma. Furthermore, HSPA8 is over-expressed in multiple myeloma and colonic carcinoma and BCR-ABL1 -induced expression of HSPA8 promotes cell survival in chronic myeloid leukemia (Dadkhah et al., 2013; Wang et al., 2013a; Chatterjee et al., 2013; Kubota et al., 2010; Jose-Eneriz et al., 2008). MDN1 was described to be a candidate tumor suppressor gene, mutated in breast cancers of the luminal B type (Cornen et al., 2014).
  • MIA3 also known as transport and Golgi organization protein 1 (TANGO)
  • TANGO transport and Golgi organization protein 1
  • CPSF6 was identified as one gene within a "poised gene cassette" associated with significant differences in metastatic and invasive potential of several tumor types, like breast, colon, liver, lung, esophageal and thyroid cancer (Yu et al., 2008).
  • NAA35 also known as MAK10
  • MAK10 encodes the N(alpha)-acetyltransferase 35, NatC auxiliary subunit.
  • a highly cancer enriched chimeric GOLM1 -MAK10 RNA was detected, which encodes a secreted fusion protein, potentially useful as molecular marker (Zhang et al., 2013b).
  • NAV2 was shown to be specifically expressed in a group of colon cancers and treatment of colon-cancer cells with antisense oligonucleotides for NAV2 induced apoptosis (Ishiguro et al., 2002).
  • NCSTN over-expression is indicative of worse overall survival in estrogen-receptor- negative breast cancer patients and high levels of Nicastrin and Notch4 were detected in endocrine therapy resistant breast cancer cells, where their activation ultimately drives invasive behavior (Sarajlic et al., 2014; Lombardo et al., 2014).
  • NKD1 protein is reduced, but NKD1 mRNA is elevated in non-small cell lung cancer, the former correlating with increased invasive potential and poor prognosis (Zhang et al., 201 1 ).
  • NKD1 mRNA was also found to be elevated in cells from human colon tumors (Yan et al., 2001 ; Zhang et al., 201 1 ).
  • NUDC In esophageal cancer, NUDC was reported to be associated with nodal metastasis, whereas over-expression of NUDC in prostate cancer cells leads to a block in cell division (Hatakeyama et al., 2006; Lin et al., 2004).
  • RINT1 is described as an oncogene in glioblastoma multiforme and as a moderately penetrant cancer susceptibility gene seen in breast cancer as well as in Lynch syndrome-related cancers (Ngeow and Eng, 2014; Quayle et al., 2012).
  • RORC reactive oxygen species
  • RPL17 was reported to promote multidrug resistance by suppressing drug-induced apoptosis (Shi et al., 2004b).
  • SAMM50 encodes a component of the Sorting and Assembly Machinery (SAM) of the mitochondrial outer membrane, which functions in the assembly of beta-barrel proteins into the outer mitochondrial membrane.
  • SAM Sorting and Assembly Machinery
  • a growth promoting chimeric mRNA (SAMM50- PARVB) was detected in breast and ovarian cancer cells and in a number of samples from breast, stomach, colon, kidney and uterus cancer (Plebani et al., 2012).
  • SERPINF2 encodes the major inhibitor of plasmin, which degrades fibrin and various other proteins.
  • the plasma level of the plasmin-alpha 2-plasmin inhibitor complex was shown to be a predictor of survival in non-small cell lung carcinoma and low activity of alpha 2-antiplasmin has been observed in the blood of the patients with prostatic carcinoma (Zietek et al., 1996; Taguchi et al., 1996).
  • Protein levels of SHC1 are elevated in prostate, metastatic breast, ovarian and thyroid cancer and different isoforms and are thought to function as a primary adaptor protein for mediating the mitogenic signals of steroids at the non-genomic level (Alam et al., 2009; Rajendran et al., 2010).
  • AMACR is used as a biomarker in prostate cancer, since it is highly over-expressed in this entity (Wu et al., 2014). Furthermore, it is used as an immunohistochemical marker for the diagnosis of renal cell carcinoma (Ross et al., 2012).
  • C1 QTNF3 expression may play a role in osteosarcoma tumor growth, associated with activation of the ERK1/2 signaling pathway and that it is a novel anti-apoptotic adipokine that protects mesenchymal stem cells from hypoxia/serum deprivation-induced apoptosis through the PI3K/Akt signaling pathway (Hou et al., 2014; Akiyama et al., 2009).
  • GPC3 is expressed by most hepatocellular carcinomas.
  • Two therapeutic approaches for HCC that target GPC3 are currently being tested in phase II clinical trials: a humanized GPC3 monoclonal antibody and a vaccine that consists of two GPC3-derived peptides.
  • the peptides used in the latter study are distinct from the peptide presented in this document.
  • GPC3 expression has also been identified in all yolk sac tumors, some squamous cell carcinomas of the lung and clear cell carcinomas of the ovary (Filmus and Capurro, 2013; Kandil and Cooper, 2009).
  • MAGEB2 is classified as cancer testis antigen, since it is expressed in testis and placenta, and in a significant fraction of tumors of various histological types, amongst others multiple myeloma and head and neck squamous cell carcinoma (Pattani et al., 2012; van et al., 201 1 ).
  • MAPKAPK5 encodes a tumor suppressor and member of the serine/threonine kinase family. MAPKAPK5 was shown to be under-expressed in colorectal cancer, leading to an increased activity of the myc oncoprotein and to decrease cancer formation by suppressing oncogenic ras activity in a murine model of hematopoietic cancer (Yoshizuka et al., 2012; Kress et al., 201 1 ).
  • C4A has been described as a biomarker for polycystic ovary syndrome and endometrial cancer and experimental data suggest that C4 can mediate cancer growth (Galazis et al., 2013; Rutkowski et al., 2010).
  • CAPZB was reported to be over-expressed in human papillomaviruses 18-positive oral squamous cell carcinomas and was identified as prostate cancer susceptibility locus (Lo et al., 2007; Nwosu et al., 2001 ).
  • CLIP1 encodes the CAP-GLY domain containing linker protein 1 , which links endocytic vesicles to microtubules. This gene is highly expressed in Reed-Sternberg cells of Hodgkin disease and breast cancer and appears to be implicated in the migration and invasion of breast cancer and pancreatic cancer cells (Sun et al., 2013; Suzuki and Takahashi, 2008; Li et al., 2014a; Sun et al., 2012).
  • CLU may inhibit tumor progression, whereas in advanced neoplasia, it may offer a significant survival advantage in the tumor by suppressing many therapeutic stressors and enhancing metastasis.
  • CLU has been shown to play a critical role in prostate cancer pathogenesis, to regulate the aggressive behavior of human clear renal cell carcinoma cells through modulating ERK1/2 signaling and MMP-9 expression and to confer resistance to treatment in advanced stages of lung cancer (Trougakos, 2013; Panico et al., 2009; Takeuchi et al., 2014; Wang et al., 2014).
  • the fusion gene SEC16A-NOTCH1 was reported as first recurrent fusion gene in breast cancer (Edwards and Howarth, 2012).
  • SLC16A1 expression is associated with poor prognostic factors and predicts tumor progression.
  • colorectal cancer single nucleotide polymorphisms in the SLC16A1 gene may affect clinical outcomes and can be used to predict the response to adjuvant chemotherapy (Kim et al., 2015; Fei et al., 2014a; Fei et al., 2014a).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules pour une utilisation dans des méthodes immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie anticancéreuse. La présente invention concerne en outre des épitopes peptidiques tumoraux de cellules T, seuls ou combinés à d'autres peptides tumoraux, qui peuvent par exemple servir en tant que principes actifs pharmaceutiques au sein de compositions vaccinales destinées à stimuler une réponse immunitaire antitumorale ou destinées à stimuler ex vivo des cellules T ensuite transférées au patient. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (CMH), ou les peptides en tant que tels, peuvent également être les cibles d'anticorps, de récepteurs solubles des cellules T, et d'autres molécules de liaison. La présente invention concerne en particulier plusieurs nouvelles séquences peptidiques et leurs variants dérivés de molécules du HLA de classe I et de classe II de cellules tumorales humaines, lesquels peuvent être utilisés dans des compositions vaccinales pour induire une réponse immunitaire antitumorale, ou comme cibles pour le développement de composés et de cellules pharmaceutiquement/immunologiquement actifs.
EP15813809.9A 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers Active EP3236985B2 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
PL19170191T PL3545965T3 (pl) 2014-12-23 2015-12-16 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
EP19199098.5A EP3616706B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
SI201531025T SI3236985T2 (sl) 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka
DK19199098.5T DK3616706T3 (da) 2014-12-23 2015-12-16 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod hepatocellulært karcinom (hcc) og andre cancere
HRP20192212TT HRP20192212T4 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
EP19170191.1A EP3545965B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
RS20191606A RS59836B2 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
EP24199595.0A EP4461371A3 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA41237A MA41237B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers
PL19199101T PL3626729T3 (pl) 2014-12-23 2015-12-16 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
EP19199125.6A EP3626731B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199106.6A EP3626730A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
PL19199125T PL3626731T3 (pl) 2014-12-23 2015-12-16 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
DK19199125.6T DK3626731T3 (da) 2014-12-23 2015-12-16 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod hepatocellulært karcinom (hcc) og andre cancere
PL19199098T PL3616706T3 (pl) 2014-12-23 2015-12-16 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (HCC) i innych rodzajów raka
DK19199101.7T DK3626729T3 (da) 2014-12-23 2015-12-16 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod hepatocellulært karcinom (hcc) og andre cancere
DK19170191.1T DK3545965T3 (da) 2014-12-23 2015-12-16 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod hepatocellulært karcinom (hcc) og andre cancere
EP19199114.0A EP3620168A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP20172206.3A EP3715357B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199101.7A EP3626729B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
PL15813809.9T PL3236985T5 (pl) 2014-12-23 2015-12-16 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii przeciwko rakowi wątrobowokomórkowemu (HCC) i innym rodzajom raka
CY20211100869T CY1124533T1 (el) 2014-12-23 2021-10-06 Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων
CY20211101070T CY1124846T1 (el) 2014-12-23 2021-12-07 Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων
CY20211101071T CY1124847T1 (el) 2014-12-23 2021-12-07 Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων
CY20211101104T CY1124813T1 (el) 2014-12-23 2021-12-15 Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων μορφων καρκινου

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462096165P 2014-12-23 2014-12-23
GB201423016 2014-12-23
GBGB1501017.6A GB201501017D0 (en) 2014-12-23 2015-01-21 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PCT/EP2015/080018 WO2016102272A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Related Child Applications (20)

Application Number Title Priority Date Filing Date
EP24199595.0A Division EP4461371A3 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP20172206.3A Division EP3715357B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19170191.1A Division-Into EP3545965B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19170191.1A Division EP3545965B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199114.0A Division-Into EP3620168A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199114.0A Division EP3620168A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199114.0A Previously-Filed-Application EP3620168A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199125.6A Division EP3626731B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199125.6A Division-Into EP3626731B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199125.6A Previously-Filed-Application EP3626731B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199098.5A Division-Into EP3616706B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199098.5A Division EP3616706B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP20172206.3A Division-Into EP3715357B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199106.6A Division-Into EP3626730A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199106.6A Division EP3626730A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199106.6A Previously-Filed-Application EP3626730A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199101.7A Previously-Filed-Application EP3626729B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199101.7A Division-Into EP3626729B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199101.7A Division EP3626729B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP20172444.0 Division-Into 2020-04-30

Publications (3)

Publication Number Publication Date
EP3236985A1 true EP3236985A1 (fr) 2017-11-01
EP3236985B1 EP3236985B1 (fr) 2019-09-25
EP3236985B2 EP3236985B2 (fr) 2022-09-07

Family

ID=52630910

Family Applications (8)

Application Number Title Priority Date Filing Date
EP20172206.3A Active EP3715357B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199114.0A Withdrawn EP3620168A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19170191.1A Active EP3545965B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199125.6A Active EP3626731B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199098.5A Active EP3616706B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199106.6A Withdrawn EP3626730A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199101.7A Active EP3626729B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP15813809.9A Active EP3236985B2 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Family Applications Before (7)

Application Number Title Priority Date Filing Date
EP20172206.3A Active EP3715357B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199114.0A Withdrawn EP3620168A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19170191.1A Active EP3545965B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199125.6A Active EP3626731B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199098.5A Active EP3616706B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199106.6A Withdrawn EP3626730A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EP19199101.7A Active EP3626729B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers

Country Status (25)

Country Link
US (8) US10064926B2 (fr)
EP (8) EP3715357B1 (fr)
JP (2) JP6906156B2 (fr)
KR (1) KR102284493B1 (fr)
CN (4) CN107001414A (fr)
AR (2) AR103220A1 (fr)
AU (3) AU2015371490B2 (fr)
BR (1) BR112017008972A2 (fr)
CA (1) CA2972126A1 (fr)
CL (1) CL2017001391A1 (fr)
CR (1) CR20170282A (fr)
DK (4) DK3626731T3 (fr)
EA (2) EA202190587A3 (fr)
GB (1) GB201501017D0 (fr)
IL (1) IL250989B (fr)
MA (3) MA40136A1 (fr)
MX (1) MX377144B (fr)
PE (1) PE20170940A1 (fr)
PH (1) PH12017500484B1 (fr)
PL (1) PL3236985T5 (fr)
RS (4) RS62237B1 (fr)
SG (1) SG11201703322UA (fr)
SI (3) SI3626729T1 (fr)
TW (1) TWI687436B (fr)
WO (1) WO2016102272A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
WO2015105955A1 (fr) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Dispositif d'acoustophorèse avec double chambre acoustophorétique
US10813984B2 (en) * 2014-04-24 2020-10-27 Rhode Island Hospital Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
KR102643923B1 (ko) 2014-12-23 2024-03-05 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
CA2969090C (fr) 2014-12-23 2023-05-02 Novartis Ag Composes triazolopyrimidine et leurs utilisations
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
WO2017221100A1 (fr) 2016-06-20 2017-12-28 Novartis Ag Composés d'imidazopyrimidine utiles pour le traitement du cancer
WO2017221092A1 (fr) 2016-06-20 2017-12-28 Novartis Ag Composés de triazolopyridine et leurs utilisations
JP7211938B2 (ja) * 2016-10-07 2023-01-24 アイオー バイオテック エーピーエス 免疫原性アルギナーゼペプチド
CA3041517A1 (fr) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Extraction par affinite de cellules par un procede acoustique
EP4317432A3 (fr) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH Récepteurs de lymphocytes t à appariement amélioré
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
IL299051A (en) * 2017-01-27 2023-02-01 Immatics Biotechnologies Gmbh New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
CN111164103A (zh) 2017-06-14 2020-05-15 西奈山伊坎医学院 检测和治疗对免疫疗法应答的肝细胞癌类别的方法
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
EP3665301B1 (fr) * 2017-08-09 2023-10-04 PamGene B.V. Procédé permettant de prédire la réponse d'un carcinome pulmonaire non à petites cellules chez des patients à un médicament
GB201713700D0 (en) * 2017-08-25 2017-10-11 Anastasis Biotec Ltd Peptide conjugates
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (fr) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reduction de la presentation d'epitope de jonction pour des neo-antigenes
WO2019118921A1 (fr) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Circuit d'excitation et circuit de commande de transducteur acoustique
EP3765071A4 (fr) * 2018-03-12 2022-05-25 The Children's Hospital of Philadelphia Procédés et compositions pour l'utilisation d'auto-antigènes tumoraux en immunothérapie adoptive
JP7606209B2 (ja) 2018-06-08 2024-12-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ アルツハイマー病および関連状態を処置するためのペプチド治療薬
DE102018122546B3 (de) * 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
CA3117879A1 (fr) * 2018-10-26 2020-04-30 Tami Bar Compositions et procedes pour la biodegradation de l'alcool
CN109663128A (zh) * 2018-11-21 2019-04-23 中国农业大学 一种肺动脉高压标志物及其作为治疗靶点的应用
JP2022512384A (ja) * 2018-12-13 2022-02-03 ロード アイランド ホスピタル Ａｓｐｈ発現腫瘍の成長および進行の阻害
EP3721899A1 (fr) 2019-04-08 2020-10-14 China Medical University Polythérapies comprenant un vaccin basé sur des cellules dendritiques et inhibiteur de point de contrôle immunitaire
CN110850086B (zh) * 2019-11-18 2023-05-02 西安交通大学 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用
CN113461798A (zh) * 2020-03-18 2021-10-01 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
CN115427812A (zh) * 2020-03-30 2022-12-02 洛菲尔生物股份有限公司 用于癌症免疫治疗的生物标记物及其用途
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
CN116333995A (zh) * 2020-07-14 2023-06-27 广州泛恩生物科技有限公司 基于cxcr6阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
CN112063718A (zh) * 2020-09-18 2020-12-11 中国医科大学 Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用
CN112043722B (zh) * 2020-09-25 2022-02-15 中国医科大学 Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用
CN114574486B (zh) * 2020-12-01 2024-04-16 中国科学院大连化学物理研究所 作用于OPLAH的siRNA、DNA及构建物和应用
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
CN114163513B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
MX2023011690A (es) 2021-04-02 2023-12-15 Amgen Inc Construcciones de unión a mageb2.
CA3226568A1 (fr) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anticorps mct11 pour traiter l'epuisement fonctionnel de lymphocytes t et ameliorer l'immunotherapie anticancereuse
CN115634281B (zh) * 2021-07-20 2025-12-02 肖伯端 Ctrp3蛋白的抗瘤作用及编码其的重组溶瘤病毒及制备方法和应用
CN113502300B (zh) * 2021-07-21 2024-02-06 徐州医科大学 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用
WO2023069933A2 (fr) * 2021-10-18 2023-04-27 Board Of Regents, The University Of Texas System Peptides et récepteurs de lymphocytes t modifiés ciblant l'antigène ndc80 et procédés d'utilisation
CN115572764B (zh) * 2022-03-30 2024-06-21 江苏鹍远生物技术有限公司 一组肿瘤检测标志物及其用途
CN116334031A (zh) * 2022-07-21 2023-06-27 中国人民解放军陆军军医大学 三个多肽及其在制备ⅰ型糖尿病免疫防治疫苗或药物中的应用
CN116042825B (zh) * 2022-09-28 2025-07-01 南方医科大学 一种评估5-fu治疗胃癌癌敏感性的探针引物组及其试剂盒
WO2024235848A1 (fr) * 2023-05-12 2024-11-21 Fundación Para La Investigación Médica Aplicada Nouveaux récepteurs de lymphocytes t
WO2025021979A1 (fr) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Nouveaux récepteurs de lymphocytes t ciblant un antigène associé au mélanome (mage) b2 et thérapie immunitaire l'utilisant
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
WO2026033136A1 (fr) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Modalités de traitement avancées pour des cellules immunitaires modifiées par tcr anti-prame
CN119524137A (zh) * 2024-12-11 2025-02-28 徐州医科大学 Fbxo22在诊断、治疗非酒精性脂肪性肝病中的应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IL59007A (en) 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020061552A1 (en) * 1999-12-17 2002-05-23 Dong Yan Mammalian dishevelled-associated proteins
WO2001062908A2 (fr) 2000-02-22 2001-08-30 Ahuva Nissim Banques d'affichage de phages chimeriques et tcr, reactifs chimeriques et tcr et methodes d'utilisation correspondantes
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
EP2322228B1 (fr) 2000-06-05 2018-01-10 Altor BioScience Corporation Protéines de fusion et conjugués de récepteurs de lymphocytes T et procédés d'utilisation de ceux-ci
WO2002007783A2 (fr) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Immunotoxines radiomarquees
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
TW200413406A (en) * 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
US20040096982A1 (en) 2002-11-19 2004-05-20 International Business Machines Corporation Methods and apparatus for analysis of mass spectra
PT1581812E (pt) * 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090075304A1 (en) 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
EP2520935A3 (fr) 2006-08-09 2013-02-13 Homestead Clinical Corporation Protéines spécifiques d'organes et leurs procédés d'utilisation
BRPI0813621A2 (pt) * 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
EA018457B1 (ru) * 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
WO2009026547A1 (fr) 2007-08-22 2009-02-26 Receptor Logi, Ltd. Procédés d'analyse de l'activité de vaccin
US8476419B2 (en) * 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009108372A2 (fr) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation
ME02267B (fr) * 2008-03-27 2016-04-28 Immatics Biotechnologies Gmbh Nouvelle immunothérapie pour le traitement de tumeurs neuronales et cérébrales
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2009151487A1 (fr) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Procédés de dosage de la puissance d’un vaccin
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
JP2013510586A (ja) 2009-11-14 2013-03-28 チュウ、カン−ユウ アテローム性動脈硬化を治療及び／又は予防するための免疫調節方法及びシステム
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2012065135A2 (fr) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Compositions immunomodulatrices, méthodes et systèmes comportant des fragments immunogènes de apob100
CA2817543A1 (fr) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Procedes et systemes immunomodulateurs pour le traitement et/ou la prevention de l'hypertension
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
EP2788012A4 (fr) * 2011-11-11 2015-08-05 Cedars Sinai Medical Center Compositions et méthodes de traitement de maladies rénales
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
EP4088737A3 (fr) * 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Peptides cibles pour la thérapie et les diagnostics du cancer colorectal
US12540318B2 (en) 2012-11-08 2026-02-03 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
WO2014160275A2 (fr) * 2013-03-14 2014-10-02 Battell Memorial Institute Biomarqueurs pour la fibrose hépatique
EP2808392A1 (fr) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer
CN103739667B (zh) * 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
EP3590958A1 (fr) 2014-03-14 2020-01-08 Immunocore Limited Banques de tcr
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
SMT202100564T1 (it) 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
CA3020555A1 (fr) 2016-04-08 2017-10-12 Adaptimmune Limited Recepteurs des lymphocytes t
KR20190059874A (ko) 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
AU2017302541B2 (en) 2016-07-27 2021-08-12 Sharp Kabushiki Kaisha Wireless telecommunications methods and apparatus using system information value tag
EP3573997A4 (fr) 2017-01-24 2020-12-09 Abexxa Biologics, Inc. Méthodes et compositions destinées à cibler un complexe comprenant un hla-i non classique et un néo-antigène dans le traitement du cancer
US20200325244A1 (en) 2020-05-18 2020-10-15 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US11497768B2 (en) 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
AU2018318303A1 (en) 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
WO2019051001A1 (fr) 2017-09-06 2019-03-14 California Institute Of Technology Signalisation et récepteurs bifonctionnels présentant des antigènes (sabr)
US20210061914A1 (en) 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
CN112236447B (zh) 2018-04-19 2023-10-20 得克萨斯州大学系统董事会 具有mage-b2特异性的t细胞受体及其用途
CN112368386A (zh) 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291116A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291127A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20190000947A1 (en) 2019-01-03
MA41237B1 (fr) 2019-12-31
CN112646025A (zh) 2021-04-13
RS62508B1 (sr) 2021-11-30
JP6906156B2 (ja) 2021-07-21
PH12017500484B1 (en) 2024-01-05
EA202190587A2 (ru) 2021-06-30
KR20170090447A (ko) 2017-08-07
RS59836B1 (sr) 2020-02-28
SG11201703322UA (en) 2017-07-28
DK3626729T3 (da) 2021-11-01
EA202190587A3 (ru) 2021-09-30
DK3616706T3 (da) 2021-11-15
EP3626731A1 (fr) 2020-03-25
PL3236985T4 (pl) 2020-12-14
US11786583B2 (en) 2023-10-17
EP3616706A1 (fr) 2020-03-04
EP3236985B2 (fr) 2022-09-07
DK3545965T3 (da) 2021-09-13
AR103220A1 (es) 2017-04-26
WO2016102272A1 (fr) 2016-06-30
SI3626729T1 (sl) 2021-11-30
CA2972126A1 (fr) 2016-06-30
EP3626731B1 (fr) 2021-09-08
US11406693B2 (en) 2022-08-09
EP3545965A2 (fr) 2019-10-02
IL250989A0 (en) 2017-04-30
AU2015371490A1 (en) 2017-03-23
BR112017008972A2 (pt) 2018-01-16
CN112646021A (zh) 2021-04-13
MA41237A (fr) 2017-11-01
PL3236985T5 (pl) 2023-03-06
PE20170940A1 (es) 2017-07-13
DK3626731T3 (da) 2021-11-22
EP3715357B1 (fr) 2024-11-06
SI3236985T2 (sl) 2023-01-31
MA40136A1 (fr) 2018-05-31
AU2020213294B2 (en) 2022-10-06
EP3626729A1 (fr) 2020-03-25
EP3620168A1 (fr) 2020-03-11
MX377144B (es) 2025-03-07
US20200405831A1 (en) 2020-12-31
JP2021104033A (ja) 2021-07-26
RS62448B1 (sr) 2021-11-30
JP7713309B2 (ja) 2025-07-25
US10064926B2 (en) 2018-09-04
EP3616706B1 (fr) 2021-10-13
CN107001414A (zh) 2017-08-01
PL3236985T3 (pl) 2020-04-30
SI3545965T1 (sl) 2021-11-30
EP3715357A1 (fr) 2020-09-30
CN112538109A (zh) 2021-03-23
MX2017008329A (es) 2017-10-26
US20200376103A1 (en) 2020-12-03
AU2015371490B2 (en) 2020-08-13
AU2020213295B2 (en) 2022-09-01
RS62237B1 (sr) 2021-09-30
EP3236985B1 (fr) 2019-09-25
AR122964A2 (es) 2022-10-19
MA49158B1 (fr) 2021-12-31
US20180207252A1 (en) 2018-07-26
SI3236985T1 (sl) 2020-01-31
AU2020213294A1 (en) 2020-09-03
AU2020213295A1 (en) 2020-09-03
EP3545965B1 (fr) 2021-07-21
EA201791150A1 (ru) 2018-03-30
TW201629096A (zh) 2016-08-16
GB201501017D0 (en) 2015-03-04
TWI687436B (zh) 2020-03-11
IL250989B (en) 2021-04-29
US20160250307A1 (en) 2016-09-01
CR20170282A (es) 2018-01-29
EP3545965A3 (fr) 2019-12-25
EP3626729B1 (fr) 2021-09-08
CL2017001391A1 (es) 2017-12-29
PH12017500484A1 (en) 2017-08-07
MA49158A (fr) 2020-03-25
US20170080070A1 (en) 2017-03-23
US20210268089A1 (en) 2021-09-02
US20180207253A1 (en) 2018-07-26
EP3626730A1 (fr) 2020-03-25
KR102284493B1 (ko) 2021-08-02
JP2018509135A (ja) 2018-04-05
RS59836B2 (sr) 2023-01-31

Similar Documents

Publication Publication Date Title
US11786583B2 (en) Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers
US20240408166A1 (en) Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
HK40028447A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
HK40016906A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180503

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246148

Country of ref document: HK

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190412

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MISSEL, SARAH

Inventor name: FRITSCHE, JENS

Inventor name: MUELLER, PHILLIP

Inventor name: WIEBE, ANITA

Inventor name: MAHR, ANDREA

Inventor name: WEINSCHENK, TONI

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MUELLER, PHILLIP

Inventor name: FRITSCHE, JENS

Inventor name: MAHR, ANDREA

Inventor name: MISSEL, SARAH

Inventor name: WIEBE, ANITA

Inventor name: WEINSCHENK, TONI

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1183158

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015038750

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20192212T

Country of ref document: HR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KATZAROV SA, CH

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 41237

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200115

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3236985

Country of ref document: PT

Date of ref document: 20200122

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20200115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190925

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190925

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192212T

Country of ref document: HR

Payment date: 20200109

Year of fee payment: 5

REG Reference to a national code

Ref country code: MD

Ref legal event code: VAGR

Ref document number: 3236985

Country of ref document: MD

Kind code of ref document: T2

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E018538

Country of ref document: EE

Effective date: 20191227

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20192212

Country of ref document: HR

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E046641

Country of ref document: HU

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190403964

Country of ref document: GR

Effective date: 20200318

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20200103

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190925

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2763911

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200601

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 33769

Country of ref document: SK

REG Reference to a national code

Ref country code: FI

Ref legal event code: P71A

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602015038750

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: FI

Ref legal event code: MDE

Opponent name: ADAPTIMMUNE LIMITED

26 Opposition filed

Opponent name: ADAPTIMMUNE LIMITED

Effective date: 20200625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190925

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192212

Country of ref document: HR

Payment date: 20201207

Year of fee payment: 6

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20201203

Year of fee payment: 6

Ref country code: MA

Payment date: 20200224

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190925

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: FI

Effective date: 20200604

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: ADAPTIMMUNE LIMITED

Effective date: 20200625

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192212

Country of ref document: HR

Payment date: 20211207

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1183158

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190925

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20211201

Year of fee payment: 7

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20220907

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602015038750

Country of ref document: DE

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E018538

Country of ref document: EE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: DE

Ref legal event code: R082

Ref document number: 602015038750

Country of ref document: DE

Representative=s name: MICHALSKI HUETTERMANN & PARTNER PATENTANWAELTE, DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: T4IZ

Ref document number: P20192212

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20221125

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: NO

Ref legal event code: TB2

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220402314

Country of ref document: GR

Effective date: 20221212

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2763911

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20230105

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 33769

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192212

Country of ref document: HR

Payment date: 20221212

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20221207

Year of fee payment: 8

Ref country code: SE

Payment date: 20221221

Year of fee payment: 8

Ref country code: RS

Payment date: 20221214

Year of fee payment: 8

Ref country code: RO

Payment date: 20221206

Year of fee payment: 8

Ref country code: PT

Payment date: 20221207

Year of fee payment: 8

Ref country code: NO

Payment date: 20221220

Year of fee payment: 8

Ref country code: NL

Payment date: 20221220

Year of fee payment: 8

Ref country code: LV

Payment date: 20221219

Year of fee payment: 8

Ref country code: LU

Payment date: 20221219

Year of fee payment: 8

Ref country code: LT

Payment date: 20221201

Year of fee payment: 8

Ref country code: IE

Payment date: 20221219

Year of fee payment: 8

Ref country code: FI

Payment date: 20221216

Year of fee payment: 8

Ref country code: EE

Payment date: 20221216

Year of fee payment: 8

Ref country code: DK

Payment date: 20221221

Year of fee payment: 8

Ref country code: CZ

Payment date: 20221205

Year of fee payment: 8

Ref country code: BG

Payment date: 20221216

Year of fee payment: 8

Ref country code: AT

Payment date: 20221216

Year of fee payment: 8

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20221130

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20221206

Year of fee payment: 8

Ref country code: IS

Payment date: 20221222

Year of fee payment: 8

Ref country code: HU

Payment date: 20221206

Year of fee payment: 8

Ref country code: HR

Payment date: 20221212

Year of fee payment: 8

Ref country code: GR

Payment date: 20221219

Year of fee payment: 8

Ref country code: BE

Payment date: 20221220

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20221220

Year of fee payment: 8

Ref country code: MK

Payment date: 20221202

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20221213

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20221205

Year of fee payment: 8

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20221209

Year of fee payment: 8

Ref country code: AL

Payment date: 20221216

Year of fee payment: 8

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1183158

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220907

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20192212

Country of ref document: HR

Effective date: 20231216

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20231216

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231216

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240617

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20240101

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 33769

Country of ref document: SK

Effective date: 20231216

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E018538

Country of ref document: EE

Effective date: 20231231

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1183158

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240617

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240101

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20240814

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231217

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231217

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231217

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240712

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20241216

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20241218

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20241219

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20241216

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250117

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250101

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

REG Reference to a national code

Ref country code: MD

Ref legal event code: KA4A

Ref document number: 3236985

Country of ref document: MD

Kind code of ref document: T3

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240701

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231217

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20221219

Year of fee payment: 8

Ref country code: MA

Payment date: 20211222

Year of fee payment: 7

Ref country code: MA

Payment date: 20210226

Year of fee payment: 6

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20200224

Year of fee payment: 5